Claims for Patent: 10,138,288

Summary for Patent: 10,138,288

Title:	Peptides and combination of peptides for use in immunotherapy against various tumors
Abstract:	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Inventor(s):	Mahr; Andrea (Tubingen, DE), Weinschenk; Toni (Aichwald, DE), Schoor; Oliver (Tuebingen, DE), Fritsche; Jens (Dusslingen, DE), Singh; Harpreet (Houston, TX), Stevermann; Lea (Tuebingen, DE)
Assignee:	IMMATICS BIOTECHNOLOGIES GMBH (Tubingen, DE)
Application Number:	15/789,567
Patent Claims:	1. A pharmaceutical composition comprising a peptide consisting of the amino acid sequence of ILQDGQFLV (SEQ ID NO. 157) in the form of a pharmaceutical acceptable salt and an adjuvant. 2. The pharmaceutical composition according to claim 1, wherein said peptide is bound to an MHC class-I or II molecule, and wherein said peptide is capable of being recognized by CD4+ and/or CD8+ T cells. 3. A fusion protein comprising a peptide consisting of the amino acid sequence of ILQDGQFLV (SEQ ID NO. 157) and N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii). 4. The pharmaceutical composition of claim 1, wherein said peptide is produced by a yeast cell or bacterial cell expression system. 5. The pharmaceutical composition of claim 1, wherein the pharmaceutical acceptable salt is a chloride salt or acetate salt. 6. The pharmaceutical composition of claim 1, wherein said peptide is produced by solid phase peptide synthesis. 7. The pharmaceutical composition of claim 6, wherein said peptide is bound to a solid-phase support. 8. The pharmaceutical composition of claim 1, further comprising a pharmaceutically acceptable carrier. 9. The pharmaceutical composition of claim 8, wherein the pharmaceutically acceptable carrier is selected from the group consisting of saline, Ringer's solution and dextrose solution. 10. The pharmaceutical composition of claim 8, further comprising pharmaceutically acceptable excipients. 11. The pharmaceutical composition of claim 10, wherein the pharmaceutically acceptable excipients are selected from the group consisting of buffers, binding agents, blasting agents, diluents, flavors, and lubricants. 12. The pharmaceutical composition of claim 8, wherein said pharmaceutical composition is a vaccine. 13. The pharmaceutical composition of claim 1, wherein the adjuvant is selected from the group consisting of anti-CD40 antibody, aluminum salts, CpG oligonucleotides and derivatives, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivates, poly-(I:C) and derivates, RNA, sildenafil, particulate formulations with poly(lactid co-glycolid) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23. 14. The pharmaceutical composition of claim 13, wherein the adjuvant comprises IL-21. 15. The pharmaceutical composition of claim 13, wherein the adjuvant comprises aluminum salts. 16. The pharmaceutical composition of claim 13, wherein the adjuvant comprises CpG oligonucleotides.

Details for Patent 10,138,288

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2035-03-27